A new review published in Oncoscience argues that the next generation of CAR-T therapy for solid tumors will depend less on making T cells simply more powerful and more on engineering them to survive, navigate and function inside one of the most hostile environments in biology. The article, titled “Engineering CAR-T cells for solid tumors: Overcoming the microenvironment through integrated design and clinical translation,” describes the solid tumor microenvironment not as a single, impenetrable barrier, but as a series of distinct biological and engineering problems that can be addressed through coordinated design. The review was published online on July 29, 2026, in Volume 13 of the journal and was led by Samuel Obiosa Onyekweli of the Department of Internal Medicine at Obafemi Awolowo University Teaching Hospital Complex in Ile-Ife, Nigeria.
Chimeric antigen receptor T-cell therapy has transformed treatment for several blood cancers by genetically programming a patient’s T cells to recognize and destroy malignant cells. Yet the same approach has produced much less impressive results in solid tumors. According to a meta-analysis cited by the authors, CAR-T therapy has achieved a pooled objective response rate of approximately 9 percent across solid malignancies. The disparity reflects the fundamentally different biology of solid cancers. Unlike many blood cancers, solid tumors form dense physical structures, contain abnormal and poorly organized blood vessels, display patchy antigen expression and create local conditions that can disable incoming immune cells.
To reach and attack a solid tumor, CAR-T cells must first leave the bloodstream and cross abnormal vasculature and dense extracellular matrix. Once inside, they encounter low oxygen, limited glucose and amino acids, high concentrations of lactic acid and suppressive metabolites. Tumor-associated macrophages, regulatory T cells, myeloid-derived suppressor cells and cancer-associated fibroblasts further reinforce immune resistance. Signals such as transforming growth factor beta can inhibit T-cell activity, while persistent exposure to tumor antigen can push CAR-T cells into exhaustion. This state is marked by altered transcriptional and epigenetic programs, reduced cytokine production, impaired proliferation and declining cytotoxicity.
The review highlights a growing shift from maximizing activation toward building cellular resilience. Earlier CAR designs often focused on stronger intracellular signaling and costimulatory domains intended to produce rapid T-cell expansion. In solid tumors, however, excessive stimulation can accelerate exhaustion. Newer strategies attempt to preserve function over time by modifying the metabolic, epigenetic and signaling systems that regulate T-cell fitness. The authors discuss c-Jun overexpression as one method of restoring AP-1-dependent transcription, a pathway involved in T-cell activation and persistence. They also examine disruption of DNMT3A, an epigenetic regulator associated with the establishment of exhaustion-related cellular states.
Additional forms of “armoring” are designed to help CAR-T cells withstand suppression after they enter the tumor. Cytokine-armored cells may be engineered to produce or respond more effectively to interleukins such as IL-10, IL-15, IL-18 or IL-21, each of which can influence survival, proliferation or effector function in different ways. Other designs interfere directly with inhibitory signals. A dominant-negative TGF-β receptor, for example, can bind suppressive cues without transmitting the full inhibitory signal into the T cell. This principle is being explored in GPC3-targeted C-CAR031 for hepatocellular carcinoma, which has reportedly produced objective response rates of approximately 50–57 percent in early clinical reports. The authors caution that these findings remain based on conference abstracts pending full peer-reviewed publication.
Getting engineered T cells to the tumor is another major challenge. Many solid tumors secrete chemokines that do not match the receptors naturally expressed by circulating T cells, leaving therapeutic cells poorly recruited to the cancer site. Adding receptors such as CCR2b may improve recognition of tumor-associated chemokine gradients and increase infiltration. Researchers are also developing hypoxia-responsive CAR systems that use the low-oxygen conditions found inside tumors as a biological switch, helping restrict activation to the tumor microenvironment. These approaches could improve both delivery and safety by reducing activity in healthy tissues where the target antigen may be present at lower levels.
Synthetic biology is adding another layer of control. SynNotch systems use one receptor to detect an initial antigen and trigger production of a second CAR, creating a sequential activation process. Tmod “NOT-gate” designs are intended to activate against malignant cells while suppressing responses to healthy cells that carry a protective antigen. Drug-controlled CARs offer yet another safety mechanism, allowing clinicians to regulate T-cell activity with an externally administered compound. Together, these circuits seek to address antigen heterogeneity, one of the defining problems of solid tumors, in which not every cancer cell displays the same target and antigen loss can allow resistant clones to survive.
The review points to several clinical developments suggesting that these principles are beginning to translate into meaningful patient outcomes. In H3K27M-mutated diffuse midline glioma, intracerebroventricular administration of GD2-targeted CAR-T cells produced substantial tumor reductions, including a complete response that was sustained beyond 30 months. In advanced gastric cancer, the CLDN18.2-targeted therapy satricabtagene autoleucel, also known as satri-cel, was reported to outperform physician’s choice in a randomized Phase 2 trial. The treatment produced a progression-free survival hazard ratio of 0.37 and an overall survival hazard ratio of 0.69, results the authors describe as the first randomized evidence of CAR-T superiority over standard treatment in a solid malignancy.
The authors stress that the engineered cell is only one part of the therapeutic system. Conditioning chemotherapy, the phenotype of T cells at infusion, manufacturing time, the patient’s gut microbiome and systemic neuroendocrine signals may all influence whether CAR-T cells persist and remain functional. Manufacturing is also undergoing rapid change, with next-day production methods and experimental technologies designed to generate CAR-T cells directly inside the patient using targeted lipid nanoparticles or receptor-targeted lentiviral particles. These approaches could reduce production delays, infrastructure requirements and treatment costs, although their safety, regulatory status and clinical feasibility remain under investigation. The review ultimately calls for an integrated development model that combines delivery, resilience, logic and whole-patient biology. It also warns that long-term genomic stability after multiplex gene editing, the safety of sustained cytokine production and the complexity of increasingly sophisticated cell products must be established through larger studies, longer follow-up and prospective biomarker-guided trials. The central message is that solid-tumor CAR-T therapy may advance not through a single breakthrough, but through the coordinated solution of many biological problems that once appeared inseparable.
Subject of Research: Not applicable
Article Title: Engineering CAR-T cells for solid tumors: Overcoming the microenvironment through integrated design and clinical translation
News Publication Date: August 11, 2026
Web References: https://doi.org/10.18632/oncoscience.666
References: Oncoscience, Volume 13; Figure 6: https://www.oncoscience.us/article/666/text/#F6
Image Credits: Copyright © 2026 Onyekweli et al.; distributed under the Creative Commons Attribution License (CC BY 4.0).
Keywords: CAR-T cell therapy, solid tumors, tumor microenvironment, cancer immunotherapy, immunotherapy engineering, synthetic biology, T-cell exhaustion, clinical translation, oncology, cellular therapy
Tags: adoptive T cell therapyCAR-T cell design strategiesCAR-T Cell Therapyclinical translation of CAR-Tengineering T cells for cancernext-generation CAR-T developmentovercoming tumor immune barrierssolid tumor microenvironmentsolid tumor treatment obstaclestargeted immunotherapytumor immunologytumor microenvironment challenges
